Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness.

PubWeight™: 1.07‹?› | Rank: Top 10%

🔗 View Article (PMC 3898963)

Published in PLoS One on January 22, 2014

Authors

Ingrid V Bassett1, Darshini Govindasamy2, Alison S Erlwanger3, Emily P Hyle4, Katharina Kranzer5, Nienke van Schaik2, Farzad Noubary6, A David Paltiel7, Robin Wood8, Rochelle P Walensky9, Elena Losina10, Linda-Gail Bekker2, Kenneth A Freedberg11

Author Affiliations

1: Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts, United States of America ; Division of General Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America ; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America ; Harvard University Center for AIDS Research (CFAR), Boston, Massachusetts, United States of America.
2: Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
3: Division of General Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America ; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
4: Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts, United States of America ; Division of General Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America ; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
5: Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
6: The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, United States of America ; Tufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts, United States of America.
7: Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, United States of America.
8: Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa ; Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
9: Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts, United States of America ; Division of General Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America ; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America ; Harvard University Center for AIDS Research (CFAR), Boston, Massachusetts, United States of America ; Division of Infectious Disease, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
10: Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts, United States of America ; Division of General Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America ; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America ; Harvard University Center for AIDS Research (CFAR), Boston, Massachusetts, United States of America ; Departments of Biostatistics and Epidemiology, Boston University School of Public Health, Boston, Massachusetts, United States of America ; Department of Orthopedic Surgery, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
11: Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts, United States of America ; Division of General Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America ; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America ; Harvard University Center for AIDS Research (CFAR), Boston, Massachusetts, United States of America ; Departments of Biostatistics and Epidemiology, Boston University School of Public Health, Boston, Massachusetts, United States of America ; Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, United States of America.

Articles citing this

Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis. Lancet HIV (2015) 1.77

Systematic review and meta-analysis of community and facility-based HIV testing to address linkage to care gaps in sub-Saharan Africa. Nature (2015) 1.58

The clinical and economic impact of point-of-care CD4 testing in mozambique and other resource-limited settings: a cost-effectiveness analysis. PLoS Med (2014) 1.32

Four models of HIV counseling and testing: utilization and test results in South Africa. PLoS One (2014) 0.90

POC CD4 Testing Improves Linkage to HIV Care and Timeliness of ART Initiation in a Public Health Approach: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.90

Finding HIV in hard to reach populations: mobile HIV testing and geospatial mapping in Umlazi township, Durban, South Africa. AIDS Behav (2015) 0.89

Challenges in initiating antiretroviral therapy for all HIV-infected people regardless of CD4 cell count. Infect Dis Poverty (2016) 0.84

Implementation and Operational Research: Cost and Efficiency of a Hybrid Mobile Multidisease Testing Approach With High HIV Testing Coverage in East Africa. J Acquir Immune Defic Syndr (2016) 0.83

Modeling and Cost-Effectiveness in HIV Prevention. Curr HIV/AIDS Rep (2016) 0.79

Modeling the Cost-Effectiveness of Home-Based HIV Testing and Education (HOPE) for Pregnant Women and Their Male Partners in Nyanza Province, Kenya. J Acquir Immune Defic Syndr (2016) 0.78

Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa. PLoS One (2016) 0.77

A Survey on Use of Rapid Tests and Tuberculosis Diagnostic Practices by Primary Health Care Providers in South Africa: Implications for the Development of New Point-of-Care Tests. PLoS One (2015) 0.77

The adult prevalence of HIV in Zambia: results from a population based mobile testing survey conducted in 2013-2014. AIDS Res Ther (2016) 0.75

Articles cited by this

Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36

Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44

Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis (2005) 9.23

Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health (2010) 8.81

Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One (2009) 8.58

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med (2006) 8.35

Universal voluntary testing and treatment for prevention of HIV transmission. JAMA (2009) 7.20

The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med (2001) 5.89

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85

Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62

Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53

Community-based intervention to increase HIV testing and case detection in people aged 16-32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. Lancet Infect Dis (2011) 4.72

HIV voluntary counseling and testing and behavioral risk reduction in developing countries: a meta-analysis, 1990--2005. AIDS Behav (2007) 4.61

Gains in life expectancy from medical interventions--standardizing data on outcomes. N Engl J Med (1998) 4.47

When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS (2005) 4.07

Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health (2007) 3.93

Removing barriers to knowing HIV status: same-day mobile HIV testing in Zimbabwe. J Acquir Immune Defic Syndr (2006) 3.63

CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr (2006) 3.39

Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med (2004) 3.06

Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96

Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr (2007) 2.91

Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr (2007) 2.71

Lost opportunities to complete CD4+ lymphocyte testing among patients who tested positive for HIV in South Africa. Bull World Health Organ (2010) 2.68

Earlier HIV diagnosis--are mobile services the answer? S Afr Med J (2010) 2.46

Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire. Antivir Ther (2003) 2.40

Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS (2005) 2.39

Linkage to HIV care from a mobile testing unit in South Africa by different CD4 count strata. J Acquir Immune Defic Syndr (2011) 2.27

Evaluation of simple rapid HIV assays and development of national rapid HIV test algorithms in Dar es Salaam, Tanzania. BMC Infect Dis (2009) 1.93

Who tests, who doesn't, and why? Uptake of mobile HIV counseling and testing in the Kilimanjaro Region of Tanzania. PLoS One (2011) 1.73

The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr (2011) 1.67

Starting a home and mobile HIV testing service in a rural area of South Africa. J Acquir Immune Defic Syndr (2012) 1.54

Efficacy of antiretroviral therapy in Africa: effect on immunological and virological outcome measures -- a meta-analysis. Int J STD AIDS (2008) 1.45

Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS (2007) 1.34

Mobile VCT: reaching men and young people in urban and rural South African pilot studies (NIMH Project Accept, HPTN 043). AIDS Behav (2013) 1.17

Linkage to HIV, TB and non-communicable disease care from a mobile testing unit in Cape Town, South Africa. PLoS One (2013) 1.14

First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS (2011) 1.10

Cost effectiveness of facility-based care, home-based care and mobile clinics for provision of antiretroviral therapy in Uganda. Pharmacoeconomics (2009) 0.94

HIV counseling and testing and access-to-care needs of populations most-at-risk for HIV in Nigeria. AIDS Care (2012) 0.83

How HIV treatment could result in effective prevention. Future Virol (2010) 0.80